Microscopic polyangiitis medical therapy

Revision as of 19:38, 1 December 2016 by Krzys617 (talk | contribs) (→‎Overview)
Jump to navigation Jump to search

Microscopic polyangiitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Microscopic polyangiitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Microscopic polyangiitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Microscopic polyangiitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Microscopic polyangiitis medical therapy

CDC on Microscopic polyangiitis medical therapy

Microscopic polyangiitis medical therapy in the news

Blogs on Microscopic polyangiitis medical therapy

Directions to Hospitals Treating Type chapter name here

Risk calculators and risk factors for Microscopic polyangiitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3]

Overview

Microscopic polyangiitis responds well to treatment with glucocorticoids such as prednisone together with a immunosuppressant such as cyclophosphamide. The combination of these 2 drugs decreases the remission of Microscopic polyangiitis by about 90%.

Medical Therapy

Induction ( 2 to 6 months)

Microscopic polyangiitis responds well to treatment with glucocorticoids such as prednisone together with a immunosuppressant such as cyclophosphamide. The dose of prednisone that is given is 1 mg/kg/day for less aggressive forms of the disease. In more aggressive forms of the disease prednisone is interchanged with methylprednisolone which is given intravenously at a dose of 1 g/kg 3 times a day. Both mild and severe forms of the disease are administered together with cyclophosphamide which is given in intravenous pulses every 2 weeks at a dose of 15 mg/kg for the first three infusions. After the first 3 doses cyclophosphamide is administered every 3 weeks at 15 mg/kg. Cyclophosphamide can also be given orally at a dose of 2 mg/kg/day, however, more side effects are seen with the oral dose, such as neutropenia.

If Microscopic polyangiitis is severe, plasmapheresis may also be given in conjunction with an immunosuppressant and glucocorticoid. Plasmapheresis has been shown to have benefit in patients with pulmonary and renal involvement.

Rituximab

Induction therapy using rituximab and glucocorticoids in a recent study conducted by RITUXVAS compared rituximab and cyclophosphamide. The trial showed no superiority, in that both medications were effective at inducing remission. However, the safety and the long term use of rituximab needs to be further addressed.

Maintenance Therapy

The maintenance therapy for Microscopic polyangiitis is with azathioprine, which is less toxic to that of cyclophosphamide. Azathioprine is administered for 18 months at a dose of 1 to 2 mg/kg/day.

Other medications that may be used as maintenance are:

  • Myclophenolate mofetil: up to 1g twice a day
  • Methotrexate: 0.3 to 25 mg/kg/week

References

Template:WH Template:WS